准备好扩展了吗?澳大利亚监管技术,全球视野

币界网Publicado a 2024-08-09Actualizado a 2024-08-09

币界网报道:

为了在全球范围内支持澳大利亚的金融科技,regtech树立了一个独特的案例。近年来,这一趋势不仅在澳大利亚,而且在更广泛的亚太地区都比以往任何时候都更加明显。Regtech在澳大利亚和亚太地区的作用和发展轨迹将是即将召开的金融巨头太平洋峰会(FMPS)的重点领域。

作为今年亚太地区最大的活动,请期待8月27日至29日在澳大利亚悉尼举行的B2B和B2C专家、专家、思想领袖等的聚会。这场盛大的峰会将吸引数千名与会者,包括众多参展商、赞助商等。

FMPS将有整整两天的精心策划的内容,这是跨越四个垂直行业——金融科技、支付、在线交易和加密货币——的广泛议程的一部分。FMPS的完整议程已经上线,鼓励参与者熟悉今年8月即将发生的事情。

今年8月,监管技术领域最受关注的小组讨论之一将是“准备好扩大规模了吗?”?澳大利亚监管技术,全球视野。事实上,近年来,可再生能源技术的重要性日益增加,并正在成为亚太地区许多人的可扩展机会。

作为一个快速提醒,现在在线预订FMPS座位还不算太晚。一定要跳过今年8月在悉尼现场的排队,今天就注册。FMPS的时间不多了,所以不要拖延!

悉尼FMPS聚焦Regtech

尽管对稳健可靠的合规性的需求日益增长,但世界第三大监管技术行业的资金仍然不足。本次会议是日历上的一个环节,通过令人大开眼界的炉边谈话来了解明天的澳大利亚监管技术中心。

小组,准备好扩大规模了吗?澳大利亚Regtech,全球视野,将于8月28日11:00-11:20在中心舞台上举行。该小组将包括两位对监管技术领域并不陌生的专家:澳大利亚科技倡导者协会全国负责人Dickie Currer和监管技术协会首席执行官Deborah Young。

小组成员可以身临其境地了解澳大利亚的监管技术领域,并找到目前该领域面临的一些关键问题的答案。参与者还可以期望找到regtech的阿尔法在哪里,以及风险投资公司错过了什么。将额外强调实际需要采取什么措施来获得更大的政府支持和协调。

当然,这带来了许多考虑和问题,也许最相关的是当地生态系统是否准备好在全球监管制度下发挥作用。值得庆幸的是,专家们可以从其他金融科技中心学到很多例子。这是一个不容错过的会议,也是澳大利亚监管技术专家最重要的会议之一。

三周后在悉尼见!

Lecturas Relacionadas

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

On August 10, 2026, BPL (300246.SZ) resumed trading after a nearly week-long suspension and immediately fell by a 20% limit-down. This plunge was triggered by the termination of a planned controlling stake transfer, dashing earlier market speculation. In January 2026, Zhejiang Quwei Zhihe Partnership entered as a significant shareholder, sparking hopes. Investors speculated that its backer, Weigu Information—a specialized "little giant" company in high-reliability solid-state storage chips—might be seeking a backdoor listing through BPL. This "cross-industry restructuring" expectation fueled a strong rally, with BPL's stock price more than doubling in 2026 prior to the halt. However, the deal was called off on August 7, directly causing the sharp sell-off. Underlying BPL's vulnerability is its fundamentally weak business. The company, a medical device firm, is mired in losses, having reported three consecutive years of net losses totaling over 200 million yuan. Its core hemodialysis business is squeezed by government procurement price cuts, while growth in its patient monitor segment has stalled. Furthermore, BPL faces imminent debt pressure with convertible bonds worth approximately 218 million yuan due in September 2026, and its current stock price is far below the conversion price. The failed control transfer may represent a delayed release of negative news, but BPL's core challenges remain: reversing operational losses and addressing its urgent liquidity crisis.

marsbitHace 2 hora(s)

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

marsbitHace 2 hora(s)

Trading

Spot
活动图片